ROIV Share Price Performance
US$20.10
7.98 (65.84%)
18.1% undervalued intrinsic discount
US$24.55
Fair Value
Price US$20.10
AnalystConsensusTarget US$24.55
Fair ValueUS$24.55
Share Pricen/a
Roivant Sciences Ltd. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
ROIV Community Narratives
AN
Fair Value US$24.55 18.1% undervalued intrinsic discount
ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term Outlook
1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term Outlook
Key Takeaways Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas. Potential in-licensing and late-stage pipeline approvals could significantly enhance earnings and portfolio sales impact.Read more
1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$24.55
18.1% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
326.15% p.a.
Profit Margin
4.29%
Future PE
290.43x
Price in 2028
US$30.44
Trending Discussion
Recently Updated Narratives
AN
ROIV: Positive Phase 3 Data Will Drive Shares Into 2026 And Beyond
Fair Value: US$24.55 18.1% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Roivant Sciences Ltd. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.01
- -2,861.53%
- -3,448.22%
- 0%
About ROIV
- Founded
- 2014
- Employees
- 750
- CEO
- WebsiteView website
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
